FDA Approves Atezolizumab for Alveolar Soft Part Sarcoma


Adults and children with unresectable or metastatic alveolar soft part sarcoma—one of the rarest types of sarcoma—can now receive treatment with atezolizumab, which was given the nod of approval by the FDA.

The FDA has approved atezolizumab (Tecentriq) to treat adults and children aged 2 years or older with unresectable or metastatic alveolar soft part sarcoma, according to a press release from the agency.

The FDA based the approval on findings of the Study ML39345 (NCT03141684) which comprised 49 patients with histologically or cytologically confirmed unresectable or metastatic alveolar soft part sarcoma.

Among patients who were treated with atezolizumab at an intravenous dose of 1200 mg/kg for adults and 15 mg/kg for children for 21 days until progression or unacceptable toxicity, the overall response rate was 24% (95% CI, 13%-39%). Among responders, the 6-month duration of response rate was 67% and the 12-month rate was 42%.

Atezolizumab was given at a recommended dose of 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks until disease progression or unacceptable toxicity. Moreover, for the pediatric population, it was 15 mg/kg every 3 weeks until progression or toxicity.

Frequent adverse effects included musculoskeletal pain (67%), fatigue (55%), rash (47%), cough (45%), nausea (43%), headache (43%), hypertension (43%), vomiting (37%), constipation (33%), dyspnea (33%), dizziness (29%), hemorrhage (29%), insomnia (27%), diarrhea (27%), pyrexia (25%), anxiety (25%), abdominal pain (25%), hypothyroidism (25%), decreased appetite (22%), arrhythmia (22%), influenza-like illness (18%),weight decreased (18%), and allergic rhinitis (16%), and weight increased (16%).


FDA grants approval to atezolizumab for alveolar soft part sarcoma. News release. FDA. December 9, 2022. Accessed December 10, 2022. https://bit.ly/3VKSSbj

Related Videos
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
There are several novel treatments that may be beneficial in several sarcoma subtypes including CAR T-cell therapies and immune checkpoint inhibitors, according to Sandra P. D’Angelo, MD.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Related Content